Inhibition of the BCR-Abl Tyrosine Kinase as a Therapeutic Strategy for CML

Oncogene - United Kingdom
doi 10.1038/sj.onc.1206081
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

BCR-ABL Tyrosine Kinase

Science-Business eXchange
2012English

Multidomain Targeting of BCR-Abl by Disruption of Oligomerization and Tyrosine Kinase Inhibition: Toward Eradication of CML

Molecular Pharmaceutics
Drug DiscoveryMolecular MedicinePharmaceutical Science
2013English

Adherence to BCR-ABL Inhibitors: Issues for CML Therapy

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2012English

Tyrosine Kinase Inhibitors in BCR-ABL Positive Acute Lymphoblastic Leukemia

Haematologica
Hematology
2015English

Inhibition of BCR Serine Kinase by Tyrosine Phosphorylation.

Molecular and Cellular Biology
Cell BiologyMolecular Biology
1996English

Evolution of BCR/ABL Gene Mutation in CML Is Time Dependent and Dependent on the Pressure Exerted by Tyrosine Kinase Inhibitor

PLoS ONE
Multidisciplinary
2015English

Combined Inhibition of MDM2 and BCR-Abl Tyrosine Kinase Targets Chronic Myeloid Leukemia Stem/Progenitor Cells in a Murine Model

Haematologica
Hematology
2019English

A Multiple Reaction Monitoring (MRM) Method to Detect BCR-Abl Kinase Activity in CML Using a Peptide Biosensor

PLoS ONE
Multidisciplinary
2013English

Protein Kinase CKIIa Interacts With the BCR Moiety of BCR/Abl and Mediates Proliferation of BCR/Abl-Expressing Cells

Oncogene
Cancer ResearchGeneticsMolecular Biology
2004English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy